135 related articles for article (PubMed ID: 24112097)
21. Prognostic significance of cytoplasmic p27 expression in human melanoma.
Chen G; Cheng Y; Zhang Z; Martinka M; Li G
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232
[TBL] [Abstract][Full Text] [Related]
22. Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.
Einspahr JG; Thomas TL; Saboda K; Nickolof BJ; Warneke J; Curiel-Lewandrowski C; Ranger-Moore J; Duckett L; Bangert J; Fruehauf JP; Alberts DS
Cancer; 2007 Dec; 110(11):2519-27. PubMed ID: 17932890
[TBL] [Abstract][Full Text] [Related]
23. Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma.
Corte MD; Gonzalez LO; Corte MG; Quintela I; Pidal I; Bongera M; Vizoso F
Int J Biol Markers; 2005; 20(4):242-8. PubMed ID: 16398406
[TBL] [Abstract][Full Text] [Related]
24. Stromal reaction in cutaneous melanoma.
Labrousse AL; Ntayi C; Hornebeck W; Bernard P
Crit Rev Oncol Hematol; 2004 Mar; 49(3):269-75. PubMed ID: 15036266
[TBL] [Abstract][Full Text] [Related]
25. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
26. Neuropeptide Y expression in cutaneous melanoma.
Gilaberte Y; Roca MJ; Garcia-Prats MD; Coscojuela C; Arbues MD; Vera-Alvarez JJ
J Am Acad Dermatol; 2012 Jun; 66(6):e201-8. PubMed ID: 21620518
[TBL] [Abstract][Full Text] [Related]
27. S100A13 is a new angiogenic marker in human melanoma.
Massi D; Landriscina M; Piscazzi A; Cosci E; Kirov A; Paglierani M; Di Serio C; Mourmouras V; Fumagalli S; Biagioli M; Prudovsky I; Miracco C; Santucci M; Marchionni N; Tarantini F
Mod Pathol; 2010 Jun; 23(6):804-13. PubMed ID: 20208480
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
[TBL] [Abstract][Full Text] [Related]
29. [Correlation between tumor cell proliferation and prognosis of primary cutaneous malignant melanoma in 127 patients].
Wang Y; Xue WC; Si L; Cui CL; Lu AP; Cao DF; Guo J; Li ZW
Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):178-81. PubMed ID: 23769437
[TBL] [Abstract][Full Text] [Related]
30. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
31. [Expression of galanin in melanocytic tumors].
Gilaberte Y; Vera J; Coscojuela C; Roca MJ; Parrado C; González S
Actas Dermosifiliogr; 2007; 98(1):24-34. PubMed ID: 17374330
[TBL] [Abstract][Full Text] [Related]
32. The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi.
Sand M; Skrygan M; Georgas D; Sand D; Gambichler T; Altmeyer P; Bechara FG
Cell Tissue Res; 2012 Oct; 350(1):119-26. PubMed ID: 22706980
[TBL] [Abstract][Full Text] [Related]
33. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.
Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L
Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890
[TBL] [Abstract][Full Text] [Related]
35. Kruppel-like factor 6 in the progression and prognosis of malignant melanoma.
Cai D; Zhao J; Sun Q
J Int Med Res; 2014 Feb; 42(1):184-90. PubMed ID: 24366496
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma.
Shimizu A; Kaira K; Kato M; Yasuda M; Takahashi A; Tominaga H; Oriuchi N; Nagamori S; Kanai Y; Oyama T; Asao T; Ishikawa O
Melanoma Res; 2015 Oct; 25(5):399-405. PubMed ID: 26237765
[TBL] [Abstract][Full Text] [Related]
37. Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF.
Depasquale I; Thompson WD
Histopathology; 2008 Mar; 52(4):500-9. PubMed ID: 18315603
[TBL] [Abstract][Full Text] [Related]
38. [Expression of neutral endopeptidase and motility-related protein-1 in cutaneous malignant melanoma].
Wu Y; Zhang XB; Liu HJ; Zheng LD; Li JW; Lin Y
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):466-9. PubMed ID: 17845760
[TBL] [Abstract][Full Text] [Related]
39. Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis.
Tu YT; Tao J; Liu YQ; Li Y; Huang CZ; Zhang XB; Lin Y
Clin Exp Dermatol; 2006 May; 31(3):413-8. PubMed ID: 16681591
[TBL] [Abstract][Full Text] [Related]
40. Association of vascular endothelial growth factor expression with patohistological parameters of cutaneous melanoma.
Gacević M; Jović M; Zolotarevski L; Stanojević I; Novaković M; Miller K; Šuljagić V; Mijušković Ž; Vojvodić D
Vojnosanit Pregl; 2016 May; 73(5):449-57. PubMed ID: 27430109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
